FDA Revises Regulatory Review Period for BRAVECTO Animal Drug

Summary

The US Food and Drug Administration (FDA) has revised the regulatory review period for the animal drug BRAVECTO after reconsideration from the applicant. The FDA published the revised review period in a notice in the Federal Register on February 12, 2018.